Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT03896958 Recruiting - Breast Cancer Clinical Trials

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

PIONEER
Start date: March 21, 2019
Phase:
Study type: Observational

The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any medical facility. Tumor tissue is saved at time of biopsy or surgery in multiple formats, including fresh and cryopreserved as a living biospecimen. SpeciCare assists with access to clinical records in order to provide information back to the patient and the patient's clinical care team. The biospecimen tumor tissue is stored in a bio-storage facility and can be shipped anywhere the patient and the clinical team require for further testing. Additionally, the cryopreservation of the biospecimen allows for decisions about testing to be made at a later date. It also facilitates participation in clinical trials. The ability to return research information from this repository back to the patient is the primary end point of the study. The secondary end point is the subjective assessment by the patient and his or her physician as to the potential benefit that this additional information provides over standard of care. Overall the goal of PIONEER is to enable best in class functional precision testing of a patient's tumor tissue to help guide optimal therapy (to date this type of analysis includes organoid drug screening approaches in addition to traditional genomic profiling).

NCT ID: NCT03895359 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma

TACE
Start date: June 2019
Phase: Phase 3
Study type: Interventional

Trans-arterial chemoembolization (TACE) is a standard treatment for patients with hepatocellular carcinoma (also called liver cancer). This is where chemotherapy is injected into the arteries of the liver and liver cancer. Unfortunately, the tumour grows after TACE in many patients. A new treatment using a specialized radiation procedure called Stereotactic ablative body radiotherapy (SBRT) may increase the chance to control liver cancer. SBRT allows radiation treatments to be focused more precisely, and be delivered more accurately than with older treatments. The purpose of this study is to find out if TACE alone versus TACE plus SBRT is better for you and your liver cancer.

NCT ID: NCT03889093 Recruiting - Clinical trials for Hepatocellular Carcinoma

Immunologic Effects of Radioembolization of Primary and Secondary Liver Malignancies

Start date: August 9, 2018
Phase: N/A
Study type: Interventional

The goal of this study is to understand the immunologic effects radioembolization has on the immune system. This will be done by evaluating the changes on biopsy, peripheral blood monocytes, and cytokines.

NCT ID: NCT03888859 Recruiting - Clinical trials for Hepatocellular Carcinoma

ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma

Start date: December 6, 2017
Phase: Early Phase 1
Study type: Interventional

Clinical study to evaluate safety (primary objectives) and efficacy (secondary objective) of ET1402L1-ARTEMIS™2 T cells in patients with alpha fetoprotein positive (AFP+ ) hepatocellular carcinoma (HCC).

NCT ID: NCT03884751 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Chimeric Antigen Receptor T Cells Targeting Glypican-3

Start date: April 11, 2019
Phase: Phase 1
Study type: Interventional

A Phase I Clinical Study of Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CAR-GPC3 T Cells) in Patients with Advanced Hepatocellular Carcinoma

NCT ID: NCT03880721 Recruiting - Clinical trials for Hepatocellular Carcinoma

By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation

Start date: January 1, 2019
Phase:
Study type: Observational

Developing a radiomics model to predict the prognosis of patients with hepatocellular carcinoma after microwave ablation to provide advice for their treatment.

NCT ID: NCT03869151 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Pretreatment Lymphocyte Monocyte Ratio on Outcome HCC Patients

Start date: April 5, 2019
Phase:
Study type: Observational [Patient Registry]

To assess the prognostic role of pretreatment LMR in hepatocellular carcinoma(HCC).

NCT ID: NCT03869034 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

TAI Combined With PD-1 Inhibitor in Locally Advanced, Potentially Resectable HCC

TAIPD1-HCC
Start date: March 25, 2019
Phase: Phase 2
Study type: Interventional

Hepatocellular carcinoma patients are mostly diagnosed at advanced stage. Nowadays, hepatic artery interventional therapy and/or systemic therapy are the main treatments options for these patients. Our previous study showed that compared to than conventional transcatheter arterial chemoembolization (TACE), transarterial infusion chemotherapy (TAI) has better objective response, better safety profile, and increased resection rates. The PD-1 inhibitors emerged in recent years have shown good momentum in the treatment of hepatocellular carcinoma. The single-drug treatment on advanced hepatocellular carcinoma has a tumor response rate of 17%, the disease control rate exceeds 60%, and the overall survival time exceeds 12 months. And it has good tolerance and less adverse events. In studies of other cancer, combined with traditional chemotherapy can further improve the efficacy of PD-1 inhibitors. Our study is a prospective, single-arm, phase II clinical study for patients with locally advanced, potentially resectable hepatocellular carcinoma (tumor confined to the hepatic stenosis with one or more branches of the portal vein). Progressive survival (PFS) is the primary end point of study. The overall survival rate, degrading resection rate, pathological response, and safety are the secondary endpoints. The efficacy and safety of TAI combined with PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma will be discussed.

NCT ID: NCT03867084 Recruiting - Clinical trials for Hepatocellular Carcinoma

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

Start date: May 6, 2019
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation. The primary hypotheses of this study are that adjuvant pembrolizumab is superior to placebo with respect to: 1) recurrence-free survival (RFS) as assessed by blinded independent central review (BICR); and 2) overall survival (OS).

NCT ID: NCT03859128 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Curative Hepatic Resection

JUPITER 04
Start date: February 28, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This study will investigate if Toripalimab (A PD-1 Inhibitor) will improve recurrence-free survival (RFS) compared to placebo in participants with HCC and are at high risk of recurrence after complete resection with no residual of tumour.